STOCK TITAN

Notifications

Limited Time Offer! Get Platinum at the Gold price until January 31, 2026!

Sign up now and unlock all premium features at an incredible discount.

Read more on the Pricing page

KIDS Files 8-K Disclosing Preliminary Revenue Estimates and Audit Caveats

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
8-K

Rhea-AI Filing Summary

Orthopedics Corp (KIDS) disclosed that it has prepared preliminary net revenue estimates but these figures are subject to completion of the company's audit and may change. The company warns that results for the third quarter and for the full year could differ materially from the preliminary estimates and cautions readers not to place undue reliance on forward-looking statements. Investors are directed to the Risk Factors discussion in the company's Annual Report filed with the SEC for factors that could cause actual results to diverge. The company also states it will not update these forward-looking estimates publicly unless required by law.

Positive

  • Preliminary estimates disclosed, indicating transparency about current revenue expectations

Negative

  • Estimates may change materially for the third quarter and the full year because they are subject to audit
0001425450FALSE00014254502023-03-112023-03-11


UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
______________________

FORM 8-K

CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
______________________

Date of Report (Date of earliest event reported): October 9, 2025
OrthoPediatrics Corp.
(Exact name of registrant as specified in its charter)
Delaware
(State or other jurisdiction of incorporation)
001-3824226-1761833
(Commission File Number)(I.R.S. Employer Identification Number)
2850 Frontier Drive
Warsaw, Indiana
46582
(Address of principal executive offices)(Zip Code)

Registrant’s telephone number, including area code: (574) 268-6379
Not Applicable
(Former name or former address, if changed since last report)
Securities registered pursuant to Section 12(b) of the Act:
Title of Each ClassTrading Symbol(s)Name of each exchange on which registered
Common Stock, $0.00025 par value per shareKIDSNasdaq Global Market

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 under the Securities Act (17 CFR 230.405) or Rule 12b-2 under the Exchange Act (17 CFR 240.12b-2).
Emerging growth company ¨
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act ¨



Item 2.02. Results of Operations and Financial Condition.

On October 9, 2025, OrthoPediatrics Corp. (the "Company”) issued a press release announcing its preliminary unaudited net revenue for the third quarter ended September 30, 2025, revised financial guidance for the year ending December 31, 2025, and provided business updates. The press release is furnished herewith as Exhibit 99.1 and is incorporated herein by reference.

The information in this Item 2.02, including the information incorporated by reference herein from Exhibit 99.1, is furnished pursuant to Item 2.02 of Form 8-K and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

The financial information set forth in this Form 8-K reflects the Company's current preliminary net revenue estimates, is subject to the completion of its audit process, and is subject to change. The Company's results for the third quarter ended September 30, 2025 could differ materially from the preliminary estimates provided in this form 8-K. The Company's net revenue for the full year ending December 31, 2025 could also differ materially from the forecasted amounts. You are cautioned not to place undue reliance on these forward-looking statements, which reflect management's analysis only as of the date of this Form 8-K. You should refer to the “Risk Factors” section of the Company’s Annual Report on Form 10-K filed with the Securities and Exchange Commission (the “SEC”) on March 5, 2025, as updated and supplemented by our other SEC reports filed from time to time, for a discussion of important factors that may cause our actual results and net revenue to differ materially from those expressed or implied by these forward-looking statements. Given these risks, uncertainties and other factors, many of which are beyond our control, you are cautioned not to place undue reliance on these forward-looking statements. The Company undertakes no obligation to publicly release the results of any revision or update of the forward-looking statements, except as required by law.

Item 9.01. Financial Statements and Exhibits.
(d)Exhibits
Exhibit No.Description
99.1
Orthopediatrics Corp. Revenue and Revised 2025 Guidance dated October 2025
104Cover Page Interactive Data File (embedded within the Inline XBRL document).
* * * * * *



SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
OrthoPediatrics Corp.
Date:   October 9, 2025By:/s/ Daniel J. Gerritzen
Daniel J. Gerritzen,
General Counsel and Secretary


- 2 -

FAQ

What did Orthopedics Corp (KIDS) disclose in this 8-K?

The company disclosed preliminary net revenue estimates and said those estimates are subject to completion of its audit and may change.

Are the preliminary revenue estimates final for KIDS?

No. The estimates are preliminary, subject to the completion of the audit process, and could differ materially.

Will KIDS update these forward-looking estimates publicly?

The company stated it will not publicly update the estimates except as required by law.

Where should investors look for risks that could affect KIDS results?

Investors should refer to the Risk Factors section of the company's Annual Report filed with the SEC for factors that may cause actual results to differ.
Orthopedia

NASDAQ:KIDS

KIDS Rankings

KIDS Latest News

KIDS Latest SEC Filings

KIDS Stock Data

466.19M
16.87M
32.71%
71.29%
4.85%
Medical Devices
Surgical & Medical Instruments & Apparatus
Link
United States
WARSAW